|
Patent landscape, scope, and claims: |
Patent 7,612,087 Scope and Claims Analysis: US “β-lactamase inhibitor” Formula (I) Compounds in Combination with β-lactam Antibiotics (ceftazidime-ceftazidime combinations)
US Patent 7,612,087 claims broad protection to a pharmaceutical composition that combines (i) a bacterial β-lactamase inhibitory compound defined by a complex Formula (I) (including multiple salt and prodrug-like variants) with (ii) a therapeutically effective amount of a β-lactamine antibiotic, with extensive downstream narrowing dependent claims that explicitly cover ceftazidime and a wide spectrum of other β-lactams.
This is not a “process-only” estate. The core claim is a combination composition claim with a structural genus defined by a bicyclic diazabicyclo scaffold bearing a sulphooxy substituent (as exemplified in dependent claim species and explicit trans isomers). The claim set also contains variant coverage via salts, different R-group substitutions, and alternative linkage forms for the sulphonyl/oxygen substituent.
What is US Patent 7,612,087 protecting: β-lactamase inhibitor composition claims with β-lactam antibiotics?
Bottom line: Claim 1 protects a composition containing an inhibitor from Formula (I) plus a β-lactamine antibiotic.
Core claim structure (independent Claim 1)
Claim 1: “A pharmaceutical composition comprising a bacterial β-lactamase inhibitory amount” of a Formula (I) compound (or pharmaceutically acceptable salt) plus “a therapeutically effective amount” of a β-lactamine antibiotic.
Key functional and structural gates:
-
Inhibitor requirement is functional, but constrained by Formula (I)
The inhibitor must be “bacterial β-lactamase inhibitory” in an amount that functions as an inhibitor, but the chemical must fit Formula (I) with specified variables (R1, R2, R3, A/X/B/…).
-
Antibiotic requirement is generic to the β-lactamine class
Claim 1 does not limit which β-lactam; dependent claims list extensive sets.
-
Strong scaffold anchoring via A, X, and sulphooxy-containing examples
Dependent claim 3/4 and the species list in claim 11 explicitly point to compounds that include:
- trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide (and salts)
- other trans isomers and related protected/ester/carboxamide variants
What “Formula (I)” effectively covers
Even though Claim 1 is written as a broad genus, it repeatedly restricts the inhibitor to a family around:
- a diazabicyclo[3.2.1]octane bicyclic β-lactamase inhibitor scaffold,
- with 7-oxo and a 6-position bearing a sulphooxy functionality (explicitly in dependent claim examples),
- with multiple options for:
- carboxamide/carboxylate forms at the 2-position (R1 and R2 permutations, including COOH, COOR, CONR6R7),
- prodrug-like substituents through ester/amide variants (R5 options include multiple carbonyl-protected forms),
- linkage alternatives via X being —C(O)—B— where B can be oxygen- or nitrogen-linked to a carbonyl-adjacent chain (n″ is fixed at 0 in the illustrated narrowed variants, and R8 is restricted to small set including H, OH, and sulphonyl phosphate/tetrazole-like groups).
“Therapeutically effective amount” implications for claim scope
Because Claim 1 is a composition claim with amounts that are “bacterial β-lactamase inhibitory” and “therapeutically effective,” the scope includes:
- fixed-dose combination products,
- admixtures intended for administration together,
- formulations where both components are present in a single dosage form,
as long as they meet functional dose conditions.
Which specific β-lactamase inhibitor species are explicitly claimed (Formula (I) enumerations)?
Featured snippet answer: Dependent Claim 3 locks in a key named species: trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3.2.1]-octane-2-carboxamide (and salts). Claim 11 enumerates a large set of additional named trans compounds and ester/carboxamide variants.
Key dependent species (directly listed)
Claim 3:
- “compound of Formula (I) comprises trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3.2.1]-octane-2-carboxamide (or salt).”
Claim 4 adds a specific antibiotic partner:
- same inhibitor species as Claim 3, plus ceftazidime.
Claim 11 is a broad “selected from” list of many Formula (I) species. It includes, among others, the following classes of compounds:
- 7-oxo-6-oxa / 6-(sulphooxy) trans diazabicyclo scaffolds
- carboxylate and carboxamide variants
- diphenylmethyl/phenylmethyl ester variants
- “sulphooxy” containing species including:
- trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxylate
- trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
- multiple N-substituted carboxamide variants (pyridylmethyl, pyridylethyl, aminocarbonylphenyl, dimethylaminophenyl, etc.)
- additional “-oxo” variants like “6-(sulphooxy)-…oct-3-in-7-one” and “3-methoxy-6-(sulphooxy)-…-oct-3-in-7-one”
What this means for enforceability
Even without a full prosecution history or claim construction record, the presence of a long explicit species list in Claim 11 indicates:
- the applicant anticipated specific commercial analogs (esters, salts, N-substituted carboxamides),
- and built a genus claim (Claim 1) supported by explicit examples that can be used as claim construction anchors.
What β-lactam antibiotics are covered: penams, cephalosporins, carbapenems, monobactams, and ceftazidime specifically?
Bottom line: Claim 1 is class-level. Dependent claims sweep widely across β-lactams. Separate dependent claims explicitly call out ceftazidime, and multiple dependent claims also list many other β-lactams and prodrug forms.
Ceftazidime is expressly targeted
- Claim 4: inhibitor species (trans-7-oxo-6-(sulphooxy)…-2-carboxamide) + ceftazidime.
- Claim 6: composition of Claim 1 where β-lactamine antibiotic comprises ceftazidime.
- Claim 16: same inhibitor as Claim 15 (sodium salt) + ceftazidime.
This creates a clear enforcement hook for fixed-dose ceftazidime–inhibitor combinations.
Broad antibiotic class coverage via dependent claims
Claim 2: antibiotics selected from:
- penams, penems, carbapenems, cephems, carbacephems, oxacephems, cephamycims, monobactams, combinations, salts.
Claim 5: cephalosporins list is extremely extensive, including:
- multiple older cephalosporins and modern ones (e.g., ceftazidime, ceftriaxone, cefepime, cefdinir, cefixime, prodrugs like cefpodoxime axetil, cefuroxime axetil, ceftazidime is explicitly in the list).
Claim 13 and Claim 14 further broaden into:
- penicillins and penam-family drugs (amoxicillin, ampicillin, piperacillin, etc.),
- cephalosporins including ceftazidime and others,
- carbapenems (imipenem, meropenem, biapenem, panipenem),
- monobactams (aztreonam, carumonam),
- combinations.
Practical scope implication
A competitor product that pairs the Formula (I) inhibitor genus with:
- any β-lactamine antibiotic that falls within the class,
is within the claim’s combination-composition theory, with stronger infringement arguments for pairings explicitly named (ceftazidime).
What claim narrowing exists: trans stereochemistry, sodium salts, and specific R-group constraints?
Bottom line: Dependent claims impose additional constraints that reduce the genus to specific trans isomers, salt form, and restricted substituent sets.
Trans stereochemistry / key scaffold substitution emphasis
- Claim 3 and Claim 4/15/16 tie directly to trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo… species.
Salt form coverage
- Claim 15: composition where Formula (I) comprises a sodium salt of
trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3.2.1]-octane-2-carboxamide.
- Claim 16 repeats sodium salt and pairs with ceftazidime.
This is important in product design because many β-lactamase inhibitor candidates and marketed compounds can be formulated as salts (or marketed as specific salt forms).
Substituent constraints in dependent claims 7-10
Claims 7-10 focus the genus by specifying:
- n = 1
- R3 = hydrogen
- R1 constrained to hydrogen or carbonyl substituents (COOR or CONR6R7) with constrained R/R6/R7 definitions
- X constrained to either oxygen-linked (—C(O)-O-(CH2)n'', n″=0) or nitrogen-linked (—C(O)-NR8-(CH2)n'', n″=0, R8 constrained)
- Claim 8: R8 is Y, Y1 or OY1
- Claim 9: R8 = OY1 (a specific restricted subset)
- Claim 10: R3 hydrogen, R1 hydrogen, and R1 limited to COOR/CONR6R7
These narrowings matter for:
- validity (support),
- infringement analysis (design-around),
- and claim charting for specific inhibitor analogs.
How broad is the genus versus the enumerated species: what design-arounds remain feasible?
Bottom line: Claim 1 is a high-constraint genus that still covers many positional and substitution variants. Design-arounds that avoid literal infringement would typically need to move outside at least one of these structural “anchors”:
- the diazabicyclo scaffold and 7-oxo motif,
- the “sulphooxy” group class implied in dependent species,
- the X/B linkage architecture (with n″ fixed at 0 in narrower variants),
- or the specific combination with a β-lactamine antibiotic in a “therapeutically effective amount.”
Where the claim is likely hardest to avoid
Given the dependent claims explicitly enumerate many “sulphooxy” trans variants, an infringing Formula (I) implementation that targets the same scaffold and sulphooxy functionalization will have difficulty escaping under Claim 1 and Claim 11.
Where design-around may be possible
Literal design-around would focus on altering at least one required structural component such that the compound no longer satisfies Formula (I) variables. Based on the claim text, the main “escape valves” are:
- changing the 6-substituent away from sulphooxy-type (or away from the defined B/X linkage leading to such functionality),
- changing the scaffold so R variables cannot be instantiated under the permitted sets,
- changing the carboxamide/carboxylate substitution patterns such that R1/R2 constraints fail.
What patent strength signals exist from the claim structure alone (without file history)?
Bottom line: The estate shows strong structural specificity (Formula (I) with many defined variables), combined with broad antibiotic class coverage and explicit ceftazidime targeting, which tends to strengthen infringement arguments for fixed-dose combinations using ceftazidime.
Supporting signals from the claim text:
- multiple dependent claims carve out the same high-value pairing (inhibitor + ceftazidime),
- multiple dependent claims lock a specific inhibitor species and then broaden to salts and alternative antibiotics.
What is the likely litigation and regulatory relevance: Orange Book listing and FDA combination products?
Constraint: This analysis uses only the claim text provided. Without knowing:
- the patent’s assignee,
- the listed FDA reference product(s),
- Orange Book entries,
- expiration and PTA,
- or any Paragraph IV / district court docket history,
it cannot produce accurate Orange Book status, generic entry timelines, or litigation dates.
Accordingly, no exclusivity timeline, FDA status, or litigation-specific conclusions are included.
How does this patent compare with common β-lactamase inhibitor composition claims in the US?
Bottom line: Compared with “method of inhibiting β-lactamases” or “process for making” claims, US 7,612,087 is positioned as a composition combination patent, typically the most direct hook for a branded fixed-dose combination product and its generic counterpart.
Key contrast points inherent in the claim text:
- Composition claim: more directly implicated by a marketed dosage form containing both inhibitor and β-lactam.
- Broad antibiotic genus in Claim 1: supports multiple product pairings if the inhibitor is used with different β-lactams.
- Explicit ceftazidime species: suggests the applicant anticipated ceftazidime-centered commercial strategy.
Key claim-by-claim coverage map (what must be present for infringement)
| Claim |
Inhibitor scope |
Antibiotic scope |
Extra narrowing |
| 1 |
Formula (I) β-lactamase inhibitory amount; includes salts |
Any β-lactamine antibiotic (functional) |
Full structural variable set in Formula (I) |
| 2 |
Formula (I) |
penams/penems/carbapenems/cephems/etc. |
Antibiotic class list |
| 3 |
Explicit: trans-7-oxo-6-(sulphooxy)-…-2-carboxamide |
not limited beyond Claim 1 concept |
Fixes inhibitor species |
| 4 |
Same as Claim 3 |
ceftazidime |
Fixes inhibitor + ceftazidime |
| 5 |
Formula (I) |
extensive cephalosporins list |
Cephalosporin-only limitation |
| 6 |
Formula (I) |
ceftazidime |
Antibiotic limited |
| 7 |
Formula (I) narrowed |
as in Claim 1 |
n=1, R3=H, X constrained, n″=0 |
| 8 |
Formula (I) further narrowed |
as in Claim 1 |
R8 constrained to Y/Y1/OY1 subset |
| 9 |
Further narrowed |
as in Claim 1 |
R8 = OY1; R2=R4=H; n″=0 |
| 10 |
Further narrowed |
as in Claim 1 |
R1 constrained to H/COOR/CONR6R7 |
| 11 |
Explicit list of many Formula (I) trans species incl. sulphooxy variants |
not limited beyond Claim 1 |
Species-selected claim |
| 12 |
Same as Claim 11 |
β-lactams as in Claim 12 list |
Adds antibiotic list |
| 13 |
Same as Claim 11 |
very wide β-lactam list (amoxicillin through carbapenems/monobactams) |
Most expansive antibiotic list |
| 14 |
Same as Claim 11 |
cephalosporin list (ceftazidime included) |
Cephalosporin-only limitation |
| 15 |
Explicit: sodium salt of trans-7-oxo-6-(sulphooxy)…-2-carboxamide |
as in Claim 1 |
Fixes inhibitor to sodium salt |
| 16 |
Claim 15 inhibitor |
ceftazidime |
Fixes inhibitor salt + ceftazidime |
Key Takeaways
- US 7,612,087 is a composition-and-combination patent: a Formula (I) β-lactamase inhibitor in defined structural space plus a β-lactamine antibiotic at therapeutically effective amounts.
- The claim set uses both genus coverage (Claim 1) and hard species anchors (Claims 3, 4, 11, 15, 16) centered on trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide and its sodium salt.
- Ceftazidime is repeatedly and explicitly targeted (Claims 4, 6, 16), strengthening infringement relevance for ceftazidime-based combination products.
- Antibiotic coverage is wide, with multiple dependent claims listing many cephalosporins, penicillins, carbapenems, and monobactams, limiting the strength of “antibiotic partner” design-arounds.
FAQs
-
Does Claim 1 require the β-lactamase inhibitor to be a specific named compound, or is it any Formula (I) compound?
Claim 1 requires the inhibitor to fall within Formula (I); dependent claims name specific species.
-
Is ceftazidime protected only for the trans-7-oxo-6-(sulphooxy)…-2-carboxamide inhibitor, or more broadly?
Ceftazidime appears in Claim 4 (with the specific inhibitor species), Claim 6 (with the broader Claim 1 inhibitor genus), and Claim 16 (with the sodium salt).
-
Do the dependent claims narrow the inhibitor to trans isomers and specific substitution patterns?
Yes. Several dependent claims explicitly require trans-7-oxo-6-(sulphooxy) scaffolds and further constrain linkage and R-group subsets.
-
Can the patent cover salt forms like sodium salts of the inhibitor?
Yes. Claim 15 explicitly covers the sodium salt of the key trans carboxamide species, and Claim 16 combines that salt with ceftazidime.
-
Is antibiotic coverage limited to cephalosporins?
No. While Claims 5 and 14 are cephalosporin-specific, Claims 2, 12, and 13 cover broader β-lactam classes including penams, penems, carbapenems, and monobactams.
References
No external sources were cited because the prompt provided only the claim text for US Patent 7,612,087 and did not include bibliographic data, assignee, prosecution dates, Orange Book listings, or litigation records.
More… ↓
⤷ Start Trial
|
